Despite the success of immunotherapy in helping many people with cancer, the majority of patients still do not respond to these treatments. There is need for continued research.On April 20, 2022, researchers at the Sloan Kettering Institute reported in the journalthat a recently discovered new immune cell"soldier" could be a good target for immunotherapy, raising hopes that it might help narrow the gap between people who respond and those who do not.
They made several startling discoveries. For one, killer innate-like T cells don't make the immune checkpoint molecule PD-1 and, as a consequence, do not appear to become exhausted the way typical killer T cells do. This is an attractive feature in a potential immune cell therapy. Lastly, unlike conventional T cells, they don't recirculate throughout the blood and lymph fluid, making stops in lymph nodes. Rather, they appear to home directly to tissues throughout the body, where they seek out danger.All of these make them of particular interest as a target of immunotherapy, Dr. Li says.
Because IL-15 isn't highly produced in healthy tissues, the killer innate-like T cells would not be spurred into action there, and therefore would not cause unwanted damage.
Many affected followers would find that of great interest. But they might also be enlightened with follow up to material accessed several years ago. It remains a case of “what happened?” 👉🏼
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
A breakthrough drug trial astonished doctors by curing rectal cancer in each patientIn a small-scale experiment being conducted on 12 patients with rectal cancer, researchers tested an immunotherapy drug called dostarlimab and the results astonished scientists with remission in every patient.
Source: IntEngineering - 🏆 287. / 63 Read more »
A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs - Nature BiotechnologyA multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs OHSUNews OHSUKnight BrighamWomens harvardmed is it a reliable source of information? Research Briefing: Identifying drug combinations that enhance treatment responses mediated by the tumor microenvironment OHSUNews OHSUKnight BrighamWomens harvardmed This is really cool
Source: NatureBiotech - 🏆 231. / 63 Read more »
Cornell Scientists Have Identified a New Incredibly Common Subtype of Prostate CancerA new and very prevalent kind of prostate cancer A recent study by a group of researchers at Memorial Sloan Kettering Cancer Center (MSK) and Weill Cornell Medicine finds that a previously unidentified subtype of hormone-resistant prostate cancer makes up roughly 30% of all cases. The study was rec
Source: SciTechDaily1 - 🏆 84. / 68 Read more »
Cancer Trials Give Immunotherapies a Boost, but Finding Right Patients Is a ChallengeCancer researchers are working to improve their understanding of who will benefit from powerful new immunotherapy treatments by zeroing in on patient or tumor characteristics. New way to ki11 people. Don’t trust them. Big Pharma will assist in the research! 'Finding right patients' Sounds like they're ordering genetically modified lab rats. Oh wait, that would be 23andme and the PCR tests along with the pandemic medical device.
Source: WSJhealth - 🏆 413. / 53 Read more »
Mosquitoes sniff out hosts infected with certain viruses, researchers findThe scientists also identified a potential way to block the scent and stop the spread of the disease using a medication already known to people struggling with acne. Ha ha stop with the bulls hit Sniffing out the SNIFFERS Checkt's die Lage.. Read 5 min. Wir brauchen Kanonenfutter für nächste Woche.
Source: NBCNews - 🏆 10. / 86 Read more »